Get the Stockscreener App
18.17
2.77%
0.49
After Hours:
18.17
Theravance Biopharma Inc stock is traded at $18.17, with a volume of 509.11K.
It is up +2.77% in the last 24 hours and up +2.19% over the past month.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$17.68
Open:
$17.72
24h Volume:
509.11K
Relative Volume:
1.19
Market Cap:
$920.72M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
-19.75
EPS:
-0.92
Net Cash Flow:
$-9.60M
1W Performance:
-2.05%
1M Performance:
+2.19%
6M Performance:
+71.25%
1Y Performance:
+84.09%
1-Day Range:
$17.48
$18.34
1-Week Range:
$17.25
$18.85
52-Week Range:
$7.90
$20.33
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
18.17 | 895.89M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-12-25 | Initiated | B. Riley Securities | Buy |
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Wall Street Zen - MarketBeat
History Review: How Theravance Biopharma Inc. stock reacts to global recession fearsRate Hike & Scalable Portfolio Growth Methods - moha.gov.vn
Why The Narrative Around Theravance Biopharma Is Shifting After Trelegy Monetization And Strategic Review - Yahoo Finance
Camber Capital Management LP Trims Stock Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
How (TBPH) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Hsbc Holdings PLC Takes Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound? - sharewise.com
Theravance Biopharma (TBPH) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Theravance Biopharma schedules 2026 annual meeting and hosts investor event By Investing.com - Investing.com Canada
Rhonda Farnum Sells 31,067 Shares of Theravance Biopharma (NASDAQ:TBPH) Stock - MarketBeat
Theravance Biopharma (TBPH) Price Target Increased by 28.23% to 27.25 - Nasdaq
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term - sharewise.com
Theravance Biopharma SVP Sells Shares Worth Over $582K - TradingView
VP Farnum Sells 31,067 ($582.5K) Of Theravance Biopharma Inc [TBPH] - TradingView
Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect? - Finviz
How Theravance Biopharma Inc. (0TB) stock reacts to fiscal policiesBond Market & Long-Term Safe Investment Plans - Newser
Why Theravance Biopharma Inc. (0TB) stock attracts HNW investorsJuly 2025 Price Swings & Advanced Technical Analysis Signals - Newser
Is Theravance Biopharma Inc. stock ready for breakoutEarnings Performance Report & Free Real-Time Market Sentiment Alerts - Newser
Oppenheimer Initiates Coverage of Theravance Biopharma (TBPH) with Outperform Recommendation - Nasdaq
VP Farnum Files To Sell 31,067 Of Theravance Biopharma Inc [TBPH] - TradingView
Oppenheimer Initiates Coverage on TBPH with Outperform Rating | - GuruFocus
Oppenheimer Initiates Theravance Biopharma at Outperform With $27 Price Target - marketscreener.com
Oppenheimer initiates Theravance Biopharma stock with Outperform rating - Investing.com
Oppenheimer initiates Theravance Biopharma stock with Outperform rating By Investing.com - Investing.com Canada
Market Trends: Will Theravance Biopharma Inc stock maintain momentum in 2025July 2025 Spike Watch & Consistent Return Investment Signals - moha.gov.vn
Why analysts recommend Theravance Biopharma Inc. (0TB) stockWeekly Profit Report & Growth Focused Investment Plans - Newser
Will Theravance Biopharma Inc. stock maintain momentum in 20252025 AllTime Highs & Accurate Trade Setup Notifications - Newser
Dir Broshy Sells 29,501 ($590K) Of Theravance Biopharma Inc [TBPH] - TradingView
Trading Systems Reacting to (TBPH) Volatility - news.stocktradersdaily.com
Theravance Biopharma stock hits 52-week high at 20.29 USD By Investing.com - Investing.com Nigeria
How Theravance Biopharma Inc. stock reacts to global recession fearsTrade Volume Report & Risk Managed Investment Signals - moha.gov.vn
Theravance Biopharma stock hits 52-week high at 20.29 USD - Investing.com
Aug Movers: Will Theravance Biopharma Inc. stock outperform Dow Jones index2025 Geopolitical Influence & Short-Term High Return Ideas - BỘ NỘI VỤ
Why Theravance Biopharma Inc. stock could outperform in 2025Weekly Risk Report & Daily Chart Pattern Signal Reports - BỘ NỘI VỤ
Theravance Biopharma (NASDAQ:TBPH) Shares Gap Up Following Analyst Upgrade - MarketBeat
BTIG Maintains Theravance Biopharma (TBPH) Buy Recommendation - MSN
Dir Broshy Files To Sell 29,501 Of Theravance Biopharma Inc [TBPH] - TradingView
TBPH: BTIG Raises Price Target to $40 While Maintaining Buy Rati - GuruFocus
Theravance Biopharma (NASDAQ:TBPH) Reaches New 12-Month HighHere's What Happened - MarketBeat
[Form 4] Theravance Biopharma, Inc. Insider Trading Activity - Stock Titan
CFO Sawaf Surrenders 18,627 Of Theravance Biopharma Inc [TBPH] - TradingView
TBPH insider filing: CFO tax-withholding of 18,627 shares at $17.90 - Stock Titan
VP Miller Surrenders 6,989 Of Theravance Biopharma Inc [TBPH] - TradingView
VP Grimaud Surrenders 19,024 Of Theravance Biopharma Inc [TBPH] - TradingView
VP Farnum Surrenders 9,060 Of Theravance Biopharma Inc [TBPH] - TradingView
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):